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Abstract
Background: Substance use disorders seem to be an under considered health problem amongst the elderly. The
Alcohol, Smoking and Substance Involvement Screening Test (ASSIST), was developed by the World Health
Organization to detect substance use disorders. The present study evaluates the psychometric properties of the
French version of ASSIST in a sample of elderly people attending geriatric outpatient facilities (primary care or
psychiatric facilities).
Methods: One hundred persons older than 65 years were recruited from clients attending a geriatric policlinic day care
centre and from geriatric psychiatric facilities. Measures included ASSIST, Addiction Severity Index (ASI), Mini-International
Neuropsychiatric Interview (MINI-Plus), Alcohol Use Disorders Identification Test (AUDIT), Revised Fagerstrom Tolerance
Questionnaire-Smoking (RTQ) and MiniMental State(MMS).
Results: Concurrent validity was established with significant correlations between ASSIST scores, scores from ASI, AUDIT,
RTQ, and significantly higher ASSIST scores for patients with a MINI-Plus diagnosis of abuse or dependence. The ASSIST
questionnaire was found to have high internal consistency for the total substance involvement along with specific
substance involvement as assessed by Cronbach’s α, ranging from 0.66, to 0.89 .
Conclusions: The findings demonstrate that ASSIST is a valid screening test for identifying substance use disorders in
elderly.
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Introduction
Despite the importance of substance use disorders
amongst the elderly and possible late onset of these dis-
orders, it seems that this health issue is underscreened
and frequently unnoticed in clinical settings [1-6]. This
appears to be of concern for substance use impact on
general and mental health. Furthermore, the pattern of
drug use has changed, during the last decade, with an in-
creasing illicit drug involvement in older adults seeking
substance abuse treatment [2].
The World Health Organization (WHO) has identi-
fied tobacco, alcohol, and prohibited drugs use as
amongst the top20 risk factors of ill-health [7]. This
consideration has led the WHO to adopt a public-
health approach for the issue, aiming to improve
screening for substance use as well as early intervention
for the problem [7].
To achieve the above mentioned aim, it is crucial to
develop a reliable and user friendly screening instru-
ment. In fact, the existing screening instruments have
several limitations for the use in primary care settings
[8]. For example, the Addiction Severity Index (ASI) [9],
is time-consuming to administer in primary care set-
tings. Furthermore, briefer instruments, such as the
CAGE-Adapted to Include Drugs [10], have a focus on
dependence, which is less useful for detecting problem-
atic or risky substance use in nondependent persons.
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from a cross-cultural perspective. In fact, most were
developed in the United States of America and do not
have documented sensitivity and specificity for use in
other cultures, and have not been extensively validated
as well.
In order to overcome these difficulties, WHO devel-
oped, The Alcohol Use Disorders Identification Test
(AUDIT), a brief, widely used and validated instrument
in primary and mental health facilities [11,12].
In order to enlarge this successful approach to other
substances, WHO developed The Alcohol, Smoking and
Substance Involvement Screening Test (ASSIST) . The in-
strument aims to screen for problematic or risky substance
use (available versions: http://www.who.int/substance_abuse/
activities/assist/en/index.html).
ASSIST (ASSIST V3.0) consists of eight questions cover-
ing tobacco, alcohol, cannabis, cocaine, amphetamine type
stimulants, inhalants, sedatives, hallucinogens, opiates and
‘other drugs’. Question 1 assesses lifetime use of sub-
stances, and the second question deals with the frequency
of substance use during the last 3 months. Answers to this
question are rated on a 5-point frequency scale ranging
from ‘never’ (in the past 3 months) to ‘daily or almost
daily’. If none of the substances have been used in the past
3 months, the interviewer can skip to the last three ques-
tions about problems and former usage patterns in their
lifetime. If any substance has been used during the past
3 months, questions 3–5 are asked, before concluding with
questions 6–8. Question 3 explores the compulsion to use
substances in the previous 3 months. This is a measure of
psychological dependence. Question 4 screens the domains
of health, social, financial or legal problems associated with
substance use within the past 3 months. Question 5
explores whether participants have failed to meet role obli-
gations. Questions 6–8 screen lifetime and recent pro-
blems, including relatives; concerns about previous
attempts to control substance use and current or lifetime
injection of drugs.
Several studies carried out around the World found
that ASSIST items were reliable and that the ASSIST
screening procedure was feasible in primary care settings
[13] as well as in psychiatric settings [14]. It was repeat-
edly found that ASSIST scores have significant correla-
tions with several other measures, such as the Addiction
Severity Index-Lite (a short version of ASI), Severity of
Dependence Scale and AUDIT. Furthermore, the instru-
ment has a good discriminative validity established on its
capacity to discriminate between substance use, abuse
and dependence for the substances tested. The scores
derived from ASSISTV3.0 are presented in Table 1 and
as presented elsewhere [14]. The specific formulae for
each domain together with the maximum score for this
domain are shown in the last column of the table.
The French version of the ASSIST was recently vali-
dated in a psychiatric and primary care setting [14].
ASSIST V3.0 to our knowledge has not been validated
amongst the elderly subgroup. The present study aims to
assess the psychometric properties of the French version
of ASSIST in an elderly sample.
Methods
Participants and procedure
One hundred participants were recruited in the University
Hospitals of Geneva between January 2010 and June 2010.
The study was systematically proposed to the patients who
attended the treatment facility during the study period
until reaching the inclusion of 100 participants. Forty-two
subjects were recruited from clients attending the geriatric
policlinic day care centre of the Department of Commu-
nity Medicine (a geriatric primary care outpatient facility).
Fifty-eight patients were recruited from geriatric psychi-
atric day-hospital.. Participants from the geriatric primary
care outpatient facility were mostly (80%) treated for at
least 3 concomitant diseases. The patients lived at home.
Fifty-two percent of them lived alone. Sixty-seven percent
of the patients needed additional at home nursing care.
The usual treatment duration at the day-hospital is 28 days.
The aim of the treatment is to improve and sustain a qual-
ity of life at home and empower the patient to be active in
his social network. The most common diagnoses were car-
diovascular diseases such as congestive heart failure (60%),
falls (65%), arthrosis associated with chronic pain (50%)
followed by other disorders, mostly polyneuropathy, dia-
betes, chronic obstructive pulmonary disease, malnutri-
tion, urinary incontinence. The patients were offered
group and individual interdisciplinary and medical treat-
ments. The patients recruited from geriatric psychiatric
day-hospital were mostly treated for mood disorders
(70%), anxiety disorders (20%) and personality disorders
(10%). The participants, received as usual outpatient care,
including medical visits, psychotherapy and nursing care
during their presence in the day-hospital. The usual treat-
ment duration at the day -hospital is between 30–50 days.
The main aim of the treatment is to maintain the patient
in his natural surroundings and empower him to have an
active role in society.
The participants received as usual outpatient care, includ-
ing, medical appointments and nursing care. Participation
in the study was voluntary and all participants were selected
by convenience sampling when they came to the clinic for
treatment. All patients were 65 years old and above.
Exclusion criteria were the followings: 1) severe cogni-
tive impairment or mental retardation; 2) Mini Mental
State score≤24/30; 3) inability to communicate in
French language; 4) Severe behavioural and mental
health disturbances; 5) drug and alcohol acute intoxica-
tion or withdrawal.
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one-time point in a face-to-face interview with a trained
psychologist or psychiatrist.
All participants gave written informed consent. The
study was approved by the Ethical committee of the
Geneva University Hospital.
Measures
Participants completed the following assessments:
– The French version of the ASSIST V3.0.[14]
– The French version of the Addiction severity index
(ASI) [15]. ASI is an interview assessing history,
frequency and consequences of alcohol and drug use.
In the present study, the subsections related to lifetime
and recent drug and alcohol use (3 months) were used.
– The French version of the AUDIT [16]. This
auto-questionnaire is a reliable and valid tool for
screening alcohol abuse and dependence.
– The French version of the Revised Fagerstrom
Tolerance Questionnaire-Smoking
Table 1 ASSIST V3.0: domain description, formula of each domain and domain maximum score
Domain
Label
Description of Domain/Score ASSIST Formula
1A Lifetime substance use – including alcohol & tobacco
P
Q1a+1b+1c+1d+1e+1f+1g+1h+1i+1j
(Max Score: 30)
1B Lifetime illicit drug use – excluding alcohol & tobacco
P
Q1c+1d+1e+1f+1g+1h+1i+1j
(Max Score: 24)
2A Global continuum of substance risk – including alcohol & tobacco
P
Q1a – j+2a– j+3a– j+4a– j+5a– j+
6a – j+7a– j+8 (Max Score: 422)
2B Global continuum of illicit drug risk – excluding alcohol & tobacco
P
Q1c – j+2c– j+3c– j+4c– j+5c– j+
6c – j+7c– j+8 (Max Score: 338)
3A Specific Substance Involvement – Tobacco (or ASSIST tobacco score)
P
2a+3a+4a+6a+7a (Max Score: 39)
3B Specific Substance Involvement – Alcohol (or ASSIST alcohol score)
P
2b+3b+4b+5b+6b+7b (Max Score: 39)
3C Specific Substance Involvement – Cannabis (or ASSIST cannabis score)
P
2c+3c+4c+5c+6c+7c (Max Score: 39)
3D Specific Substance Involvement – Cocaine (or ASSIST cocaine score)
P
2d+3d+4d+5d+6d+7d (Max Score: 39)
3E Specific Substance Involvement -ATS (or ASSIST ATS score)
P
2e+3e+4e+5e+6e+7e (Max Score: 39)
3F Specific Substance Involvement – Inhalants (or ASSIST inhalants score)
P
2f+3f+4f+5f+6f+7f (Max Score: 39)
3G Specific Substance Involvement – Sedatives (or ASSIST sedatives score)
P
2g+3g+4g+5g+6g+7g
(Max Score: 39)
3H Specific Substance Involvement – Hallucinogens (or ASSIST hallucinogen score)
P
2h+3h+4h+5h+6h+7h
(Max Score: 39)
3I Specific Substance Involvement – Opioids (or ASSIST opioid score)
P
2i+3i+4i+5i+6i+7i (Max Score: 39)
3J Specific Substance Involvement – Other
P
2j+3j+4j+5j+6j+7j (Max Score: 39)
4A Total Current Frequency of Substance Use – including alcohol, *excluding
tobacco & ‘other drugs’
P
Q2b – i (Max Score: 48)
4B Total Current Frequency of Illicit Drug Use – *excluding alcohol, tobacco
& ‘other drugs’
P
Q2c – i (Max Score: 42)
4C Current Frequency alcohol use Q2b (Max Score: 6)
4D Current Frequency cannabis use Q2c (Max Score: 6)
4E Current Frequency cocaine use Q2d (Max Score: 6)
4F Current Frequency amphetamine use Q2e (Max Score: 6)
4G Current Frequency inhalant use Q2f (Max Score: 6)
4H Current Frequency sedative use Q2g (Max Score: 6)
4I Current Frequency hallucinogen use Q2h (Max Score: 6)
4J Current Frequency opioid use Q2i (Max Score: 6)
5A Dependence – all substances including alcohol & tobacco
P
Q1a – j+2a– j+3a– j+6a– j+7a– j
(Max Score: 270)
5B Dependence – illicit drugs excluding alcohol & tobacco
P
Q1c – j+2c– j+3c– j+6c– j+7c– j
(Max Score: 216)
6A Abuse – all substances including alcohol & tobacco
P
Q1a – j+2a– j+4a– j+5a– j+6a– j
(Max Score: 300)
6B Abuse – illicit drugs, excluding alcohol & tobacco
P
Q1c – j+2c– j+4c– j+5c– j+6c– j
(Max Score: 240)
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– The French version of the Mini-International
Neuropsychiatric Interview (MINIPlus)[18].
In the study at hand, the sections of the MINIPlus
related to drug and alcohol abuse and dependence (life-
time and past 12 months) were administered.
This allows eliciting the presence or absence of de-
pendence and/or abuse for: (i) alcohol (ii) the two other
most frequently used drugs by the participants as
assessed by ASSIST.
Furthermore, in order to exclude from the study
patients with severe mental impairment, the participants
also underwent a screening with the MINI MENTAL
STATE questionnaire [19].
Data analysis
Data was analyzed with SPSS (version 18.0, IBM, Chicago,
USA) Proportions, mean values and standard deviations
were used to describe the baseline characteristics for each
group. We investigated the psychometric properties of
ASSIST V3.0 by studying its criterion validity and con-
struct validity. Criterion validity comes in two forms:
concurrent validity where the new scale and the criter-
ion are administered at approximately the same time
and predictive validity where the new scale is meant to
predict some later criterion [20]. We used the concurrent-
type validity since the ASSIST was simultaneously
administered with other existing validated instruments
or administered within a short time of one another. Sev-
eral domains or scores derived from the ASSIST together
with scores from other questionnaires namely, the AUDIT,
the MINI-Plus, the Fagerström and the ASI were used in
the validation process. The ASSIST consists of eight ques-
tions, covering ten substances: tobacco, alcohol, cannabis,
cocaine, amphetamine type stimulants (ATS), inhalants,
sedatives, hallucinogens, opioids and “other drugs”.T e s t
results are reported as significant for p<0.05.
The correlations between the ASSIST domain scores
and other similar instrument scores were assessed using
Pearson’s correlations. For instance, the ASSIST tobacco
scores were correlated with Fagerström scores and
ASSIST alcohol scores were correlated with AUDIT.
ASSIST specific substance involvement (SSI) scores for
each substance were also compared in the presence or
the absence of MINI-Plus diagnosis of current or life-
time abuse or dependence. A, two-tailed t-tests (or
Mann–Whitney tests) were used where assumptions of
variance homogeneity were violated. Finally, the total
substance involvement score, excluding tobacco, was
compared to the total number of MINI-Plus diagnosis
which comprised the sum of current and life-time diag-
nosis of abuse and dependence for all drugs except
tobacco. Internal consistency refers to the extent to
which the items are interrelated. Cronbach’s coefficients
were computed. This index varies between 0 and 1 and
translates a greater degree of homogeneity of the items if
its value is close to 1. Actually, its computation is based
on the number of items on the survey and the ratio of
the average inter-item covariance to the average item
variance. It is generally accepted that the internal
consistency of an instrument is satisfactory when the
value of the coefficient is above 0.70 but not much
higher than 0.90 [20]. The ASSIST was investigated for
its ability to discriminate between three groups: non-
problematic use, abuse and dependence. Clinically these
three groups reflect the risk status of patients – that is,
low, moderate or high risk. Risk status is proportional to
the ASSIST score achieved. For a specific substance,
people were classified in the low risk group if they scored
0 on the MINI-plus current abuse and dependence diag-
nosis (patient without substance abuse nor dependence).
They were classified in the moderate risk group if they
scored 1 for current abuse and 0 for current dependence.
Finally the high risk group was composed of people with 0
for current abuse and 1 for current dependence diagnosis.
Specific substance scores were compared using independ-
ent groups’ analysis of variance (ANOVA) with Games-
Howell’s post-hoc test. Games-Howell does not assume
that sample variances are equal or that sample sizes are
equal. Hence it is a good alternative if this turns out to be
the case. The same groupings were also used to perform
receiver operating characteristic (ROC) analysis in order to
obtain further information concerning the ability of the
ASSIST to discriminate between groups.
Results
Sample characteristics
One hundred (100) patients, of whom 42 were from com-
munity medicine and 58 from general psychiatry, were
interviewed for this study. Of this total, 28% were men.
Age ranged from 65 to 93, with a mean of 77.8 ± 7.5 years.
Except for age and nationality, no other statistical differ-
ences between groups were observed (Cf. Table 2). Patients
with cognitive impairment (MINI Mental State≤24/30)
were not included in the present study.
Concurrent validity
1) Comparison with the Addiction Severity Index (ASI),
Audit and Fagerström
ASSIST scores for alcohol had large positive correla-
tions with the ASI and the AUDIT scores: (r=0.73 and
p<0.0005; r=0.8 and p<0.0005 respectively). ASSIST
tobacco scores also showed a large positive significant
correlation with the Fagerström test (r=0.8; p<0.0005).
No correlation could be computed for ASSIST and ASI
opioids scores due to a lack of information.
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Participants recording current or life-time abuse or de-
pendence diagnosis on the MINI-Plus had significantly
higher ASSIST scores for alcohol compared with those for
whom the same diagnosis was absent (Table 3). It is worth
noting that out of the 19 participants with alcohol use dis-
order, 63.2% were females with an ASSIST mean score of
12.8 ±9.4 compared to 4.3±5.9 for men.
Table 2 Socio-demographic and addiction data by place of recruitment
Total Community medicine
(n=42)
General psychiatry
(n=58)
p-value*
Mean age in years (± DS) 77.8 (7.5) 81.2 (6.3) 75.4 (7.4) <0.0005
Gender, n (%) 0.09
- male 28 19 34.5
- female 72 81 65.5
Civil status, n(%) 1
- married 38 38.1 37.9
- single/divorced/separated/widow 62 61.9 62.1
Nationality, n (%) 0.002
- Swiss 75 88.1 60.3
- other 25 11.9 39.7
Higher school grade, n (%) 0.7
- elementary school 39 35.7 41.4
- apprenticeship 21 19 22.4
- secondary school and higher 40 45.2 36.2
Mean AUDIT score (± DS) 2.9 (4.8) 3.3 (5.1) 2.7 (4.6) 0.5
Mean ASSIST score (± DS)
- tobacco 2.3 (5.3) 2.4 (6) 2.2 (4.9) 0.8
- alcohol 3.7 (5.3) 4.3 (6.4) 3.3 (4.4) 0.4
- Cannabis 0. (0) 0 0
- Cocaine 0. (0) 0 0
- ATS 0. (0) 0 0
- Inhalants 0. (0) 0 0
- Sedatives 0.2 (1.1) 0.3 (1.6) 0.05 (0.4) 0.2
- Hallucinogens 0. (0) 0 0
- opioids 0. (0) 0 0
*Obtained by Student t-test or chi-square test/Fisher exact test respectively.
Table 3 Comparison of ASSIST specific substance scores according to the presence or absence of MINI Plus current or
life-time diagnoses of abuse or dependence
Mean ASSIST scores
by substance type
mean (SD), n
Does subject meet MINI Plus criteria for current or lifetime
diagnosis of abuse or dependence for a specific substance?
T-value
(p- value)
Diagnosis present: Diagnosis absent:
Tobacco na na na
Alcohol 10 (8.5), 19 2.2 (2.6), 81 -3.9 (p=0.001)
Cannabis 0 (na), 1 0 (0), 99 na
Cocaine na, 0 0 (0), 100 na
ATS na, 0 0 (0), 100 na
Inhalants na, 0 0 (0), 100 na
Sedatives na, 0 0.2 (1.1), 100 na
Hallucinogens na, 0 na, 100 na
Opioids 0 (na), 1 0 (0), 99 na
na: sample size too small to allow comparison or information not available from questionnaire.
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tobacco) correlated well with the total number of MINI-
Plus diagnosis (r=0.71 and p<0.0005).
Construct validity
Internal consistency
T h eA S S I S Tq u e s t i o n n a i r ew a sf o u n dt oh a v eag o o di n -
ternal consistency for the Global continuum substance risk
score or the total substance involvement score (TSI) with a
Cronbach’s α coefficient of 0.72 (95% CI 2 [0.63, 0.79],
p<0.0005). Moreover, ASSIST scores for alcohol, tobacco
and sedatives also showed moderate to good internal
consistency (0.66, 0.74 and 0.89 respectively). The calcula-
tion of Chronbach’s α for the other substances was not pos-
sible due to insufficient data.
Discriminative validity
Table 4 shows specific substance scores grouped by diag-
nosis for non-problematic use (low risk), abuse (moder-
ate risk) and dependence (high risk). Valid ANOVA
results could be produced only for alcohol and not for
the other substances due to insufficient data.
Discrimination between use and abuse and between
abuse and dependence could not be further investigated
by ROC curves because there were no valid observations.
As a result, estimation of sensitivity and specificity of the
instrument could not be performed.
Discussion
The results of this study indicate that the French version
of the ASSIST is an acceptable and valid screening test
for substance abuse and dependence in the short elderly
sample. The findings are convergent with previous works
on the validity of the ASSIST as a screening instrument
for substance use disorders [7,13,14].
Concurrent validity of the French version of the ASSIST
V3.0 was demonstrated by significant positive correlations
between ASSIST scores and ASI, MINI-Plus, AUDIT and
RTQ. The ASSIST has a good internal consistency, Cron-
bach’s α, ranging from 0.66 to 0.89.
The present, results show that ASSIST is a good and
potentially useful instrument in general and psychiatric
elderly health care settings.
This finding seems to be of great interest for clinical
settings, considering the usually under screening of sub-
stance use disorders in elderly [2,5].
In comparison to previous screening-instruments,
ASSIST has several advantages such as :
1. Screening for a wide range of substance use disorders.
This is an advantage in comparison to others
instruments such as the AUDIT [16]o rt h eR T Q[ 17].
2. Short duration time of the questionnaire and a user-
friendly aspect. This is an advantage in comparison
to instruments like (ASI) [15].
3. Detection of substance use, abuse and dependence.
This characteristic may be of particular interest
with elderly helping to brake barriers, highlight the
difficulties and possibly taboos related to the
investigation of substance use disorders in elderly.
The present study has several limitations, such as the
moderate sample size, a sample recruited only in Univer-
sity public outpatient facilities, the rarity of certain sub-
stance use in this sample, therefore, the estimates for
sensitivity and specificity, for a number of substances
could not be calculated. Furthermore, the study sample
was not a general population sample. Future studies on
large samples may be of great interest for the assessment
of substance use disorders in primary care facilities and
for further investigation of the ASSIST instrument.
The study presents however these findings for alcohol,
the substance most widely used (19 participants have abuse
or alcohol dependence). Despite the rarity of a number of
substances misuse in at least the present sample, screening
Table 4 Comparison of ASSIST domain scores for non-problematic use, abuse and dependence
Domain Use (low risk) Abuse (moderate risk) Dependence (high risk) F-value, p-value G-H
Mean (SD), n Mean (SD), n Mean (SD), n
3A: SSI score for tobacco na
a na na na na
3B: SSI score for alcohol 2.9 (3.2), 89 na 22.7 (9.6), 4 -3.5, p<0.0005
b na
3C: SSI score for cannabis 0 (0), 100 na, 0 na, 0 na na
3D: SSI score for cocaine 0 (0), 100 na, 0 na, 0 na na
3E: SSI score for ATS 0 (0), 100 na, 0 na, 0 na na
3F: SSI score for Inhalants 0 (0), 100 na, 0 na, 0 na na
3G: SSI score for sedatives 0 (0), 100 na, 0 na, 0 na na
3H: SSI score for hallucinogens 0 (0), 100 na, 0 na, 0 na na
3I: SSI score for opioids 0 (0), 100 na, 0 na, 0 na na
ainformation not available from questionnaire or unable to perform post hoc test because there are fewer than 3 groups.
bcomparison by Mann–Whitney test because only 2 non-empty groups and too small sample size.
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wide range of substances which is an important value added
aspect in comparison to other screening instruments. These
characteristics would be of great interests considering the
lack of well validated drug misuse screening instrument for
the aged [21] and also in consideration of the importance of
alcohol and drug misuse in the elderly and particularly
among the aged with comorbid psychiatric disorders [22].
Despite these limitations, our results suggest that the
French version of the ASSIST could be used as part of a
more general public health approach to the screening of
substance use disorders in the elderly healthcare facilities.
Further studies may assess impact of linking therapeutic
interventions such as brief interventions to ASSIST
screening in elderly people. As suggested by the WHO,
this may help to reduce the burden of substance use disor-
ders which are important risk factors of ill-health [7].
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